Holen Sie sich die Stockscreener-App
102.03
7.63%
7.235
Handel nachbörslich:
102.87
0.84
+0.82%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$94.80
Offen:
$95.19
24-Stunden-Volumen:
2.63M
Relative Volume:
1.20
Marktkapitalisierung:
$16.15B
Einnahmen:
$4.34B
Nettoeinkommen (Verlust:
$-965.00M
KGV:
-16.81
EPS:
-6.07
Netto-Cashflow:
$869.00M
1W Leistung:
+5.02%
1M Leistung:
+12.75%
6M Leistung:
-27.31%
1J Leistung:
-13.25%
1-Tages-Spanne:
$95.11
$102.29
1-Wochen-Bereich:
$92.25
$102.29
52-Wochen-Spanne:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
102.03 | 15.38B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
What analysts say about Illumina Inc. stockStrong return on assets - jammulinksnews.com
Lobbying Update: $410,000 of ILLUMINA INC. lobbying was just disclosed - Quiver Quantitative
DNA Test Kits Market Booming with Consumer Genomics Demand - openPR.com
Bioinformatics Services Market Surge Backed by Genomics - openPR.com
Illumina Inc. Stock Analysis and ForecastUnstoppable profit momentum - jammulinksnews.com
What drives Illumina Inc. stock priceExceptional profit potential - jammulinksnews.com
Illumina India Wins the Top GCC Award at the 2025 GCC Workplace Awards - ThePrint
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 - GlobeNewswire Inc.
ILLUMINA, INC. (ILMN) - MSN
Is Illumina Inc. a good long term investmentStrongest growth potential - jammulinksnews.com
Published on: 2025-07-19 09:23:06 - jammulinksnews.com
Killer acquisitions: what the future holds post-Illumina — Consumer Competition Market Blog - Faculteit Rechtsgeleerdheid en Criminologische Wetenschappen
Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche - Yahoo Finance
Illumina’s SWOT analysis: genomics giant faces headwinds as stock outlook shifts - Investing.com
March 2026 Options Now Available For Illumina (ILMN) - Nasdaq
Illumina Stock: What Went Wrong And Why It's Best To Stay Away - 富途牛牛
Single-Cell Omics Market Growth in Future Scope 2025-2032 |10x - openPR.com
DNA Microarray Market Size, Industry Growth Insights Report - openPR.com
Bioinformatics Market Set to Witness Significant Growth by 2033 - openPR.com
How To Trade (ILMN) - news.stocktradersdaily.com
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Illumina stock downgraded at Scotiabank (ILMN:NASDAQ) - Seeking Alpha
Scotiabank Downgrades Illumina to Sector Perform From Sector Outperform, Reduces Price Target to $125 From $164 - MarketScreener
Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025 - 富途牛牛
Industry Focus eBook: Infectious diseases - News-Medical
Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year - PR Newswire
Illumina Achieves Double Recognition: #2 Most Sustainable US Company and Best Workplace Excellence - Stock Titan
Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit - simplywall.st
Illumina Shares Fall After Citigroup Downgrade - MarketScreener
Why Illumina (ILMN) Shares Are Falling Today - Yahoo Finance
Illumina: Citigroup downgrades to 'Sell' Rating, The Target Price is $80 - AInvest
Illumina stock down as Citi cuts on recent rally (ILMN:NASDAQ) - Seeking Alpha
Illumina Shares Slip After Citi Issues Bearish Rating Ahead of Earnings - MSN
Illumina Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Where Illumina Stands With Analysts - Nasdaq
Illumina (ILMN) Stock Trades Down, Here Is Why - Yahoo Finance
Illumina to Acquire SomaLogic for $350 Million, Expanding into Proteomics and Precision Medicine - Yahoo Finance
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic - Nasdaq
Illumina, Inc. (ILMN): A Bull Case Theory - Insider Monkey
Illumina doubles down on multiomics with $350m SomaLogic acquisition - Longevity.Technology
Illumina to buy SomaLogic in deal worth up to $425M - BioPharma Dive
Happy International Women in Engineering Day! - Illumina
Infinity Bio Secures $8M Series A and Acquires Serimmune to Dominate Antibody Reactome Market - Stock Titan
DNA/Gene Microarray Market Future Trends and Scope Analysis - openPR.com
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):